spirapril and Diabetes-Mellitus--Type-2

spirapril has been researched along with Diabetes-Mellitus--Type-2* in 3 studies

Trials

2 trial(s) available for spirapril and Diabetes-Mellitus--Type-2

Article	Year
[Quadropril (spirapril) in the treatment of isolated systolic hypertension in patients with type 2 diabetes mellitus]. Kardiologiia, 2006, Volume: 46, Issue:7 Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Treatment Outcome	2006
[Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function]. Terapevticheskii arkhiv, 2000, Volume: 72, Issue:10 To examine effectiveness and safety of quadropril.. Changes in blood pressure (BP), heart rate (HR), levels of glucose, potassium and creatinine, creatinine clearance were studied in 120 patients (48 males and 72 females, mean age 60.6 +/- 0.7 years) with mild to moderate arterial hypertension (AH) with average duration 13.8 +/- 0.7 years. The patients were divided into 3 groups: with AH (n = 40), AH + noninsulindependent diabetes mellitus (DM) (n = 43), AH and nephropathy (n = 37). 8-week treatment was performed with a standard dose of 6 mg/day (1 tablet of quadropril). Control examinations were made 2, 4 and 8 weeks after the treatment.. After 8 weeks of treatment a decrease in systolic blood pressure in AH group was 24.0 +/- 3.0 mm Hg and in diastolic blood pressure 16.3 +/- 1.3 mm Hg (P < 0.001). In the group with DM this decrease was 22.4 +/- 2.8 mm Hg and 15.7 +/- 1.4 mm Hg (p < 0.001), respectively. In the group with nephropathy this decrease was 26.4 +/- 2.4 and 16.5 +/- 1.3 mm Hg (p < 0.001), respectively. Heart rate changed significantly only in diabetics: from 75.1 +/- 1.7 to 72.9 +/- 1.3 beats/min. Biochemical parameters in the hypertensive and diabetic patients did not change significantly. In the nephropathy group there was a significant decrease in creatinine and increase in creatinine clearance. Their level of glucose and potassium changed insignificantly.. The treatment with quadropril results in a significant decrease in blood pressure, does not influence parameters of carbohydrate metabolism, improves nitrogen eliminating function of the kidneys. Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Safety; Treatment Outcome	2000

Article

Year

[Quadropril (spirapril) in the treatment of isolated systolic hypertension in patients with type 2 diabetes mellitus].

Kardiologiia, 2006, Volume: 46, Issue:7

Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Treatment Outcome

2006

[Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function].

Terapevticheskii arkhiv, 2000, Volume: 72, Issue:10

To examine effectiveness and safety of quadropril.. Changes in blood pressure (BP), heart rate (HR), levels of glucose, potassium and creatinine, creatinine clearance were studied in 120 patients (48 males and 72 females, mean age 60.6 +/- 0.7 years) with mild to moderate arterial hypertension (AH) with average duration 13.8 +/- 0.7 years. The patients were divided into 3 groups: with AH (n = 40), AH + noninsulindependent diabetes mellitus (DM) (n = 43), AH and nephropathy (n = 37). 8-week treatment was performed with a standard dose of 6 mg/day (1 tablet of quadropril). Control examinations were made 2, 4 and 8 weeks after the treatment.. After 8 weeks of treatment a decrease in systolic blood pressure in AH group was 24.0 +/- 3.0 mm Hg and in diastolic blood pressure 16.3 +/- 1.3 mm Hg (P < 0.001). In the group with DM this decrease was 22.4 +/- 2.8 mm Hg and 15.7 +/- 1.4 mm Hg (p < 0.001), respectively. In the group with nephropathy this decrease was 26.4 +/- 2.4 and 16.5 +/- 1.3 mm Hg (p < 0.001), respectively. Heart rate changed significantly only in diabetics: from 75.1 +/- 1.7 to 72.9 +/- 1.3 beats/min. Biochemical parameters in the hypertensive and diabetic patients did not change significantly. In the nephropathy group there was a significant decrease in creatinine and increase in creatinine clearance. Their level of glucose and potassium changed insignificantly.. The treatment with quadropril results in a significant decrease in blood pressure, does not influence parameters of carbohydrate metabolism, improves nitrogen eliminating function of the kidneys.

Topics: Administration, Oral; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Creatinine; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Safety; Treatment Outcome

2000

Other Studies

1 other study(ies) available for spirapril and Diabetes-Mellitus--Type-2

Article	Year
[Hypertensive patient with diabetes. "Blood pressure cosmetics" are not enough here]. MMW Fortschritte der Medizin, 2002, Jun-13, Volume: 144, Issue:24 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Diabetes Mellitus, Type 2; Enalapril; Evidence-Based Medicine; Humans; Hypertension; Treatment Outcome	2002